Don’t miss your chance to enroll. SWTX Summer and Fall 2026 registration is now open, so it's time to secure your classes and stay on track.
GET STARTED: bit.ly/4sIcQ7e
$PBLS 3.7B MC
Good story but too expensive
$SWTX was aquired for 3.4B, 1.5y after nirogacestat approval in desmoid
PBLS will start ph3 in desmoid in h1'27. Other trails are in early ph1.
Hard pass
I'm not super familiar with their data but if the ph2 desmoid tumor looks good, I assume someone is out there figuring that SWTX looks vulnerable and that location alone could be worth 4-6B for a good drug
$PBLS The most advanced program targets desmoid tumors. Relevant for $IMNM ($2.1B MC) and $SWTX (bought by MerckKGaA for $3.4B). The IPO seems a bit overpriced to me, but the $REGN investment is a strong sign. Parabilis is added to the watchlist.
Ditto $insm .. another case of mis-mgmt of analysts / expectations / comms joining the likes of $slno$apls$gern$iova$swtx ( $abvx and $cytk (Blum may have turned corner)) .. all unique sits/ TAs but consistent variable is you (investor) listen to conference call / presentation and say “would love to have been fly-on-wall when they decided that was good idea”
$insm maybe Will Lewis should spend less time on space travel and more time managing analyst / investor expectations
With that said, is Insmed vulnerable down here??